Your essential biotech, medtech, and pharma recap — no noise, just what matters.

⚡ Executive Takeaway

The China licensing wave we have tracked since the BMS/Hengrui deal on May 12 just accelerated dramatically. In a single day, Pfizer signed a $10.5B deal with Innovent for 12 oncology programs and Lilly signed a $3B+ deal with Haisco for five programs. Add BMS/Hengrui ($15.2B, 13 programs), Merck/Kelun-Biotech (sac-TMT, multiple Phase 3 wins), GSK/SiranBio ($1B, ALK7), AbbVie/Haisco (Nav1.8), and Lilly/Hengrui (via Kailera), and the West-to-China licensing pipeline now exceeds $50B in announced potential value in 2026 alone. The strategic rationale is unchanged: Chinese biotechs produce high-quality clinical-stage assets at lower development costs. Western pharma gets pipeline optionality. Chinese companies get upfront cash and downstream economics. But the geopolitical tension is intensifying. The COINS Act push to restrict outbound capital to Chinese biotech is gaining Congressional momentum at the exact moment the deal flow is hitting record levels. Meanwhile, GSK's KIT inhibitor data from ASCO suggest the company may have another franchise-level asset from its IDRx acquisition. And Lilly's deal count has reached 11 in under six months, a pace that may be without precedent in pharma history. 👉 Read Full Analysis

🔮 What To Watch

🚀 Top Story

Pfizer and Innovent Sign $10.5B Oncology Licensing Deal PFE

Pfizer and China's Innovent Biologics agreed to a global licensing and collaboration deal worth up to $10.5B to co-develop 12 early-stage cancer medicines, according to Lambda Biologics and multiple outlets. The deal includes an undisclosed upfront payment plus development and commercial milestones. Pfizer gains rights to develop and commercialize the programs outside Greater China. Innovent retains Greater China rights. Specific targets and indications have not yet been disclosed. This is the largest single China licensing deal of 2026 by total potential value, surpassing BMS/Hengrui ($15.2B but across 13 programs vs. Pfizer/Innovent's 12).

Lilly Adds $3B+ Haisco Partnership as Its 11th Deal of 2026 LLY

Eli Lilly signed a partnership worth more than $3B with China's Haisco Pharmaceutical Group spanning five programs, according to BioSpace. This expands on the earlier AbbVie/Haisco Nav1.8 pain deal and signals that Haisco has become one of the most active Chinese licensors alongside Hengrui and Kelun-Biotech. Lilly and Haisco have yet to disclose specific indications. This is Lilly's 11th deal of 2026, bringing total announced deal value above $28B.

📊 China Licensing Scorecard: 2026

Total announced potential value: more than $30B across 37+ programs. Total including undisclosed terms: likely exceeds $50B.

🔬 Clinical & Research Updates

GSK KIT Inhibitor Could Overtake Gleevec in GIST

Fierce Biotech reported that GSK shared early ASCO data suggesting its KIT inhibitor, acquired through the IDRx deal, could overtake Novartis's Gleevec (imatinib) as the standard of care for gastrointestinal stromal tumors (GIST). Gleevec has been the GIST backbone for more than two decades. A next-generation selective KIT inhibitor with improved efficacy and tolerability could capture significant share in a market Gleevec has dominated for more than two decades. Detailed data will inform whether GSK pursues a pivotal trial.

Ivonescimab Detailed Data Draw Scrutiny

Fierce Pharma reported that while ivonescimab's 34% improvement in overall survival exceeded expectations, detailed data from the HARMONi-6 trial "are being picked apart" by analysts and oncologists. Key questions center on the comparator (tislelizumab, not Keytruda), the Chinese-only enrollment, and whether the benefit translates to Western patient populations. Summit Therapeutics (U.S. partner) will need to address these concerns as it plans its U.S. regulatory strategy.

📅 The Week Ahead

On one hand: Congress is pushing to add biotechnology to the COINS Act, which would restrict U.S. capital flows to Chinese biotech. China's Decree No. 834 gives Beijing new powers to investigate foreign companies. The geopolitical tension is real and intensifying.

On the other hand: BMS signed $15.2B with Hengrui. Pfizer signed $10.5B with Innovent. Lilly signed $3B+ with Haisco. GSK signed $1B with SiranBio. AbbVie signed with Haisco. Merck's Kelun-Biotech partnership just produced two Phase 3 wins. All in a single month.

The disconnect is stark. The political rhetoric says "decouple." The deal flow says "accelerate." Both things are happening simultaneously. The resolution will come in one of three ways:

For BD teams: assume the current deal window remains open but may not last indefinitely. If you are evaluating Chinese assets, the window to close deals may be narrowing.

💊 Lilly: 11 Deals, $28B+, Six Months

Updated running total:

Total: approximately $28.9B+ across 11 deals in under six months.

🎯 Catalyst Calendar: June 2026 Forward

👉 Visit The Pro Hub

Is your company listed in the BioMed Nexus directory? 2,104 companies across 14 categories. Claim or upgrade your listing →

Sponsorship slots for 2026 are limited. See packages and pricing →

NEW: BioMed Nexus Signals, weekly sales intelligence for life sciences BD teams. Learn more →